Clearside Biomedical
Biotechnology, 900 N Point Pkwy Ste 200, Alpharetta, Georgia, 30005, United States, 11-50 Employees
Phone Number: 67********
Who is CLEARSIDE BIOMEDICAL
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). Clearsides SCS injection...
Read More
-
Headquarters: 900 N Point Pkwy Ste 200, Alpharetta, Georgia, 30005, United States
-
Date Founded: 2012
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
George Lasezkay
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from CLEARSIDE BIOMEDICAL
Clearside Biomedical Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Clearside Biomedical
Answer: Clearside Biomedical's headquarters are located at 900 N Point Pkwy Ste 200, Alpharetta, Georgia, 30005, United States
Answer: Clearside Biomedical's phone number is 67********
Answer: Clearside Biomedical's official website is https://clearsidebio.com
Answer: Clearside Biomedical's revenue is $10 Million to $25 Million
Answer: Clearside Biomedical's SIC: 2834
Answer: Clearside Biomedical's NAICS: 325412
Answer: Clearside Biomedical has 11-50 employees
Answer: Clearside Biomedical is in Biotechnology
Answer: Clearside Biomedical contact info: Phone number: 67******** Website: https://clearsidebio.com
Answer: Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). Clearsides SCS injection platform, utilizing the Companys proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearsides first product, XIPERETM (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month